» Articles » PMID: 39802260

Critical Insights into Novel Immunomodulatory Therapy for Sepsis: Evaluating Promise Amidst Limitations

Overview
Date 2025 Jan 13
PMID 39802260
Authors
Affiliations
Soon will be listed here.
Abstract

Angadi VM, Kambagiri P, Jindal A. Critical Insights into Novel Immunomodulatory Therapy for Sepsis: Evaluating Promise Amidst Limitations. Indian J Crit Care Med 2025;29(1):90.

References
1.
Li X, Liu C, Mao Z, Qi S, Song R, Zhou F . Effectiveness of polymyxin B-immobilized hemoperfusion against sepsis and septic shock: A systematic review and meta-analysis. J Crit Care. 2020; 63:187-195. DOI: 10.1016/j.jcrc.2020.09.007. View

2.
Jain A, Singam A, Mudiganti V . Recent Advances in Immunomodulatory Therapy in Sepsis: A Comprehensive Review. Cureus. 2024; 16(3):e57309. PMC: 11059166. DOI: 10.7759/cureus.57309. View

3.
Robey R, Logue C, Caird C, Hansel J, Hellyer T, Simpson J . Immunomodulatory drugs in sepsis: a systematic review and meta-analysis. Anaesthesia. 2024; 79(8):869-879. DOI: 10.1111/anae.16263. View

4.
Ghosh I, Sangha S, Pandey G, Srivastava A . Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis. Indian J Crit Care Med. 2024; 28(10):930-934. PMC: 11471987. DOI: 10.5005/jp-journals-10071-24805. View

5.
Mithal L, Arshad M, Swigart L, Khanolkar A, Ahmed A, Coates B . Mechanisms and modulation of sepsis-induced immune dysfunction in children. Pediatr Res. 2021; 91(2):447-453. PMC: 9752201. DOI: 10.1038/s41390-021-01879-8. View